AIKIUM
Therapeutics Targeting GPCRs with SeqR Proteins
Enabled by breakthroughs in Artificial Intelligence and Synthetic Biology, Aikium Inc. is targeting GPCRs (such as Chemokine Receptors) in Oncology, Auto-Immune Diseases and Neuro-Inflammatory Disorders with a novel class of protein biologics capable of binding to intrinsically disordered regions of proteins.
The SeqR (“seeker”), a proprietary non-antibody scaffold engineered from a privileged human protein, seeks sequence epitopes on disordered regions of target proteins
Yotta-ML² is the platform that enables Yotta (10²⁴) - scale machine learning (ML) on massive libraries (ML) of SeqRs, with the world’s only trillion-protein mRNA display for large proteins and patented generative AI based on protein language models
We are interested in your hardest problems.
Our platform is able to routinely produce nanomolar binders to disordered epitopes from a wide variety of targets, often where antibody and small molecule based approaches have failed.
Let’s partner and bring new therapies to life.
Scientific Advisory Board
-
Prof. George Church
Harvard, MIT, Wyss
-
Dr. Kevin Yang
DEEP LEARNING FOR PROTEINS EXPERT
Microsoft Research
-
Dr. Mark Lebwohl
Mt. Sinai, New York
-
Dr. Nicolas Gaudenzio
INSERM, Genoskin
-
Dr. Mette Rosenkilde
Univ. of Copenhagen, Bainan, Synklino, Antag Tx
-
Prof. Lawrence Stern
U Mass Med School, MIT
-
Dr. Tarjei Mikkelsen
CTO, Arsenal Bio
Interested in backing a transformative technology about to define the next decade in protein biologics? Our Series Seed campaign just opened.
Founders
Aikium beckons!
Be a part of the foundational team that is working on a transformative approach with the potential to lead to 100 therapies within a decade
